BioSpace News Archive

Cytokinetics, Incorporated announced that on February 28, 2023 it granted stock options to purchase an aggregate of 21,450 shares of common stock to 5 new employees, whose employment commenced in February 2023, as a material inducement to their employment.

NeuroPace, Inc., a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, reported financial results for the fourth quarter and full-year ended December 31, 2022.

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™(PGS), today announced its operating and financial results for the fourth quarter and full year 2022.

Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today highlighted recent corporate achievements and reported financial results for the fourth quarter and full year ended December 31, 2022.

Neuronetics, Inc. announced criteria changes by United HealthCare Optum to their commercial plans that increase eligibility for depression patients to receive treatment with NeuroStar Advanced Therapy for Mental Health transcranial magnetic stimulation.

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, reported financial results for the three and twelve months ended December 31, 2022.

Terns Pharmaceuticals, Inc. announced that management will participate in three upcoming investor conferences in March 2023 and provided program updates across the Company’s development programs as outlined below.

NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today provided a business update and reported full year 2022 financial results.

Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, today announced that Sean Bohen, M.D., Ph.D., President and Chief Executive Officer, will present at the Oppenheimer 33rd Annual Healthcare Conference on Wednesday, March 15, 2023, at 2:40 p.m. ET.

Seer, Inc., a life sciences company commercializing a disruptive new platform for proteomics, reported financial results for the fourth quarter and full year ended December 31, 2022.